Get Clarity, Not Just Headlines.

Published 1 day ago • loading... • Updated 1 day ago

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist

Summary by KITV4 News

SAN DIEGO, June 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of investigational compound NBIP-01435 in healthy adult participants.…

18 Articles

18 Articles

All

Left

1

Center

7

Right

Aspen Daily News

+17 Reposted by 17 other sources

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist

SAN DIEGO, June 30, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of investigational compound NBIP-01435 in healthy adult participants.…

1 day ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Coverage Details

Total News Sources18

Leaning Left1Leaning Right0Center7Last Updated2 hours agoBias Distribution

88% Center

Bias Distribution

88% of the sources are Center

88% Center

+2

Untracked bias

+1

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

PR Newswire broke the news in United States 1 day ago on Monday, June 30, 2025.

Sources are mostly out of (0)

Similar News Topics

Similar News Topics

You have read 1 out of your 5 free daily articles.

Join millions of well-informed readers who use Ground to compare coverage, check their news blindspots, and challenge their worldview.